No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	AFM13/AB-101 Sensitive: B - Late Trials AFM13 / AB-101 Sensitive : B	AFM13/AB-101 Sensitive: B - Late Trials AFM13 / AB-101 Sensitive : B
TNFRSF8 positive	Lymphoma	TNFRSF8 positive	Lymphoma	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	AFM24 Sensitive: C2 – Inclusion Criteria AFM24 Sensitive : C2	AFM24 Sensitive: C2 – Inclusion Criteria AFM24 Sensitive : C2
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	AFM13 Sensitive: C3 – Early Trials AFM13 Sensitive : C3	AFM13 Sensitive: C3 – Early Trials AFM13 Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	atezolizumab + AFM24 Sensitive: C3 – Early Trials atezolizumab + AFM24 Sensitive : C3	atezolizumab + AFM24 Sensitive: C3 – Early Trials atezolizumab + AFM24 Sensitive : C3
TNFRSF17 underexpression	Multiple Myeloma	TNFRSF17 underexpression	Multiple Myeloma	CTX-8573 Sensitive: D – Preclinical CTX-8573 Sensitive : D	CTX-8573 Sensitive: D – Preclinical CTX-8573 Sensitive : D
EGFR expression	Triple Negative Breast Cancer	EGFR expression	Triple Negative Breast Cancer	AFM24 Sensitive: D – Preclinical AFM24 Sensitive : D	AFM24 Sensitive: D – Preclinical AFM24 Sensitive : D

CD16A agonist

CD16A agonist

Associations(8)

Associations
(8)